Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in an early study.
Dr. Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background,...
Thanks in part to the recent completion of an $8m investment, 2020 On-site plans to expand its services, including the mobile support of vision research.
InMed Pharmaceuticals is developing a gel-based cannabinoid drug for eye diseases such as glaucoma, which it says could be cheaper and more accessible than cannabinoid-based products on the market.
Fujifilm has introduced an anti-counterfeiting label, called ForgeGuard, which it claims is the first product with full colour images and text that can be checked using a viewing device.
Researchers at the University of Derby in the UK are appealing for
industrial partners to join their research programme into tackling
problems associated with misleading medicine labels, difficult drug
names and package designs.